Compare Wells Fargo & Co (WFC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wells Fargo & Co vs State Street SPDR S&P Biotech ETF — how do they compare? Wells Fargo & Co trades at $88.87 (market cap $264.66B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Wells Fargo & Co pays a 2.29% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Wells Fargo & Co nearer its low. Which is the better fit depends on your goals.
| WFC | XBI | |
|---|---|---|
Market Cap | $264.66B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $96.40 | $164.28 |
52-Week Low | $73.42 | $86.92 |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wells Fargo (WFC) trades at $89.15, up 1.82% for the day, with a bullish technical signal from moving averages and a consensus analyst price target of $97.64. Recent earnings show a Q2 2026 beat but misses in prior quarters, while revenue and net income have grown steadily from 2022 to 2025. The company is expanding into digital services like tokenized deposits, announced in August 2026, to enhance corporate client offerings.
The stock presents a value opportunity with a P/E of 12.72 and strong profitability metrics, including a 25.97% net income margin. Risks include volatile cash flows, with operating cash flow negative in 2025, and competitive pressures in banking. Analyst sentiment is mixed but leans positive, with 45% buy ratings, supporting potential upside if execution improves.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
